Marisa Wexler, MS, senior science writer —

The first cystic fibrosis (CF) patient has been dosed in Part A of a Phase 2 clinical trial in Europe that’s testing Enterprise Therapeutics‘ novel CF treatment candidate ETD001. The Phase 2a trial (NCT06478706) is still recruiting adults with CF at a few sites in the U.K. and…

Authorities in the U.S. and Europe are reviewing applications from Vertex Pharmaceuticals seeking approval of the company’s novel CFTR modulator triple combination, vanzacaftor, tezacaftor and deutivacaftor.  Vertex is asking that the vanza combo be approved for people with cystic fibrosis (CF) ages 6 and older who carry…

During pulmonary exacerbation in cystic fibrosis (CF), bacterial communities in the lungs tend to change in one of two general patterns, and better understanding these patterns may help predict how patients will respond to antibiotic treatments. That’s according to the study, “Microbial community organization designates distinct…

Two Massachusetts-based companies, Nanite and Saliogen Therapeutics, are teaming up on a new research project that aims to create a genetic medicine with the potential to treat cystic fibrosis (CF). “Nanite’s relationship with SalioGen is consequential in discovering safe polymeric nanoparticles for a transformative treatment for CF,”…

This year’s “Fishing for a Cure,” an annual fundraiser hosted by Constellation Energy Corporation, has raised $70,000 for the Cystic Fibrosis Foundation, a nonprofit that helps to support people living with cystic fibrosis (CF) and to fund research for new treatments. “We are in shock by the incredible…

Evoq Bio said it successfully completed a meeting with the U.S. Food and Drug Administration (FDA), held to discuss the development of its inhaled nanoparticle therapy for treating bacterial lung infections in people with cystic fibrosis (CF) and other lung disorders. According to the company, a subsidiary of…

Phage therapy, a promising strategy for treating antibiotic-resistant lung infections that’s currently in clinical trials, can trigger the release of inflammatory signaling molecules from human lung cells, with different types of phages triggering a different set of signaling molecules. That’s according to a study, “Lytic bacteriophages induce…

Treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) helps increase fat stores in adults with cystic fibrosis (CF), especially those who are underweight, a study found. Researchers also found small, though statistically significant, increases in muscle mass in patients who started on Kaftrio. The results showed that Kaftrio mainly affects fat tissues,…

Infections of Pseudomonas aeruginosa usually persist in people with cystic fibrosis (CF) after Trikafta is started, a study reports. The study, “Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis,” was published in mBio. CF is…

A test of physical function called Glittre-ADL may be better than the standard six-minute walk test at identifying physical limitations in people with cystic fibrosis (CF), a study reports. “To our knowledge, this is the first study to evaluate the performance of CF patients on TGlittre and to compare…